US 11401512
Engineered target specific nucleases
granted A61KA61K38/465A61K38/47
Quick answer
US patent 11401512 (Engineered target specific nucleases) held by Sangamo Therapeutics, Inc. expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 33
- CPC classes
- A61K, A61K38/465, A61K38/47, A61K38/4846, A61K48/00